All In Biotech

Drug Trial Radar · NCT07903441

Multiple Interventions With Distinct Anti-reservoir Activities in People on Antiretroviral Treatment

Phase 2b Clinical Trial Using Multiple Interventions With Distinct Anti-Reservoir Activities In People On Antiretroviral Treatment

Last checked: Nov 19, 2026Latest source record: Oct 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

70

Planned (sponsor's estimate)

Start

Aug 1, 2026

Primary completion

Jul 31, 2027

Study completion Dec 31, 2027

Sponsor

Lead sponsor
Federal University of São PauloAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Weill Medical College of Cornell University
First posted
Oct 29, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Factorial
Masking
None
Primary purpose
Basic science
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Contemporary ART fails to eradicate the HIV-1 virus from PWH, resulting in a rebound in viremia within days to weeks after cessation of ART. Evidence indicates that disparities in biological and sociocultural characteristics between resource-limited and resource-privileged settings affect treatment outcomes. Consequently, resource-constrained settings must possess the capability to comprehend the mechanisms and drivers of HIV persistence, as well as to devise and evaluate therapies for HIV cure or prolonged remission within local populations. The investigators will employ genomic, metabolomics, and transcriptomics to analyze samples from a successful therapeutic trial we conducted in Brazil, a resource-constrained country, to identify and investigate mechanisms of HIV persistence and we will employ novel latency-reversal agents and advanced in vivo cell therapy. The clinical trial the investigators will conduct will employ a multifaceted intervention strategy to achieve HIV remission through intensified ART to reduce residual HIV replication, a novel combination of latency reversal agents (LRA), and cell therapy utilizing autologous dendritic cells infused with autologous HIV peptides.

Conditions

  • HIV - Human Immunodeficiency Virus

Interventions

  • Multiple therapeutic interventionsDrug

    intensified antiretroviral treatment using 2 NRTIs, dolutegravir, boosted darunavir/r, and maraviroc or Leronlimab, (ii) use of the HDACi nicotinamide Riboside or nicotinamide, and dendritic cell therapy using peptides of autologous HIV. After the intervention, participants will undergo analytical treatment interruption of antiretrovirals (ATI) and will be closely followed to monitor rebound of HIV viremia.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Evolution of viral load of HIV RNA over the time frame of the study by ultrasensitive RT-qPCRTime frame: baseline, weeks 12, 24, 36 and 48 and every 3 weeks after the antiretroviral ATI up to 36 months after antiretroviral ATI
  2. Evolution of cell-associated HIV RNA in PBMCs by qPCR. over the study time frameTime frame: baseline, weeks 12, 24, 36 and 48 and every 3 weeks after the antiretroviral ATI up to 36 months after antiretroviral ATI
  3. Evolution of total DNA and episomal HIV DNA in lymphoid tissue (rectal biopsy)Time frame: baseline, week 48, after resurgence of viremia in the analytical interruption of antiretrovirals, or after 24 and 96 weeks after analytical interruption of antiretrovirals.
  4. Evolution of percentages of CD38 and HLA DR in CD4 + and CD8 + T lymphocytesTime frame: baseline, weeks 12, 24, 36 and 48 and every 3 weeks after the antiretroviral ATI up to 36 months after antiretroviral ATI
  5. Evolution of the HIV RNA sequence of the V3 region of gp 120, protease, reverse transcriptase and integrase regions of the pol gene, and of the gag geneTime frame: baseline, week 24, week 48, after resurgence of viremia after ATI and before reintroduction of ART
  6. Evolution of plasma cytokines IL-2, IL-4, IL-6, IL-10, IL-17, TNF and IFN-γTime frame: baseline, week 24, week 48, after resurgence of viremia after ATI and before reintroduction of ART

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Laboratório de Retrovirologia, UNIFESP

    São Paulo, São Paulo, Brazil · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.